Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair

Year
2006
Type(s)
Author(s)
Majsterek, Ireneusz and Sliwinski, Tomasz and Poplawski, Tomasz and Pytel, Dariusz and Kowalski, Michal and Slupianek, Artur and Skorski, Tomasz and Blasiak, Janusz
Source
Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 603(1): 74—82, 2006
Url
http://www.sciencedirect.com/science/article/pii/S138357180500286X
BibTeX
BibTeX